Implantica Achieves Key Milestone in FDA Approval for RefluxStop® Device
Implantica AG, a prominent player in the MedTech sector, recently reached a significant benchmark in its journey towards gaining FDA approval for its innovative RefluxStop® device, designed for the treatment of acid reflux, which afflicts over one billion individuals worldwide. The completion of the '100-Day Meeting' with the U.S. Food and Drug Administration (FDA) is an important step in the Premarket Approval (PMA) review process. This meeting serves as a platform for the company and the FDA team to engage on preliminary findings, address any outstanding inquiries, and confirm pathways forward for the application.
Dr. Peter Forsell, CEO and founder of Implantica, expressed optimism following the meeting, emphasizing the constructive nature of the dialogue with the FDA. He stated, "The 100-Day meeting provided valuable insights regarding what the FDA requires as we advance in the PMA review process. Armed with this feedback, we are now prepared to finalize the necessary additional information requested by the agency."
The PMA review process is notably complex, but Implantica appears confident that it is nearing the finish line. As part of the ongoing review, the FDA is set to conduct audits at one hospital site, the Implantica site itself, and two of its production facilities throughout October and November. Simultaneously, the company will perform additional testing as required by the FDA. The final decision from the agency is anticipated to come roughly 92 days after Implantica submits its responses.
The RefluxStop® device represents a new frontier in the treatment of acid reflux, standing apart from traditional surgical solutions. Unlike conventional methods that involve encircling the esophageal passageway, which often leads to undesirable side effects such as difficulty swallowing and inability to belch, RefluxStop® addresses the underlying cause of acid reflux without applying pressure. This innovative approach aims to restore and support the natural physiology of the lower esophageal sphincter, thereby offering a more human-centered solution.
Not only does RefluxStop® restore the natural positioning of the lower esophageal sphincter, but it also reconstructs critical components of the anti-reflux barrier, making it a potentially game-changing treatment option. With successful clinical trial outcomes backing its efficacy, this technology could lead to a significant shift in how gastroesophageal reflux disease (GERD) is managed.
Implantica is additionally committed to advancing eHealth initiatives, further enhancing its offerings in the realm of healthcare technology. Their robust pipeline includes patent-protected innovations designed to monitor health parameters and manage treatment remotely, embodying a comprehensive approach to patient care.
For more information and updates on Implantica, the RefluxStop® device, and its pivotal developments, stakeholders are encouraged to visit their official website or reach out through their media contacts. The anticipation surrounding the upcoming FDA decision adds to the excitement for this novel technology, which stands to redefine acid reflux treatment and improve the quality of life for countless patients worldwide.
Dr. Peter Forsell, CEO and founder of Implantica, expressed optimism following the meeting, emphasizing the constructive nature of the dialogue with the FDA. He stated, "The 100-Day meeting provided valuable insights regarding what the FDA requires as we advance in the PMA review process. Armed with this feedback, we are now prepared to finalize the necessary additional information requested by the agency."
The PMA review process is notably complex, but Implantica appears confident that it is nearing the finish line. As part of the ongoing review, the FDA is set to conduct audits at one hospital site, the Implantica site itself, and two of its production facilities throughout October and November. Simultaneously, the company will perform additional testing as required by the FDA. The final decision from the agency is anticipated to come roughly 92 days after Implantica submits its responses.
The RefluxStop® device represents a new frontier in the treatment of acid reflux, standing apart from traditional surgical solutions. Unlike conventional methods that involve encircling the esophageal passageway, which often leads to undesirable side effects such as difficulty swallowing and inability to belch, RefluxStop® addresses the underlying cause of acid reflux without applying pressure. This innovative approach aims to restore and support the natural physiology of the lower esophageal sphincter, thereby offering a more human-centered solution.
Not only does RefluxStop® restore the natural positioning of the lower esophageal sphincter, but it also reconstructs critical components of the anti-reflux barrier, making it a potentially game-changing treatment option. With successful clinical trial outcomes backing its efficacy, this technology could lead to a significant shift in how gastroesophageal reflux disease (GERD) is managed.
Implantica is additionally committed to advancing eHealth initiatives, further enhancing its offerings in the realm of healthcare technology. Their robust pipeline includes patent-protected innovations designed to monitor health parameters and manage treatment remotely, embodying a comprehensive approach to patient care.
For more information and updates on Implantica, the RefluxStop® device, and its pivotal developments, stakeholders are encouraged to visit their official website or reach out through their media contacts. The anticipation surrounding the upcoming FDA decision adds to the excitement for this novel technology, which stands to redefine acid reflux treatment and improve the quality of life for countless patients worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.